Current management strategies for hepatitis B in the elderly

Area of Science:

• Hepatology
• Virology
• Public Health

Background:

• Chronic hepatitis B virus (HBV) infection is a significant global health issue, with 350 million carriers at risk of severe liver disease.
• Hepatocellular carcinoma (HCC) screening is crucial for the elderly due to the long-term nature of HBV infection and emerging treatments.

Purpose of the Study:

• To review current antiviral therapies for chronic hepatitis B, focusing on treatment considerations for the elderly population.
• To evaluate lamivudine as a treatment option in the elderly, considering its efficacy, safety, and potential for drug resistance.

Main Methods:

• Literature review of chronic hepatitis B management strategies.
• Analysis of antiviral therapies including interferon-alpha (IFN alpha) and lamivudine.
• Discussion of pharmacokinetic considerations and adverse effects in elderly patients.

Main Results:

• Antiviral treatment for chronic hepatitis B is indicated for patients with elevated transaminases, HBV replication, and liver inflammation.
• Lamivudine may be preferable for the elderly due to fewer general adverse effects compared to IFN alpha, with no dose adjustment needed unless renal impairment is present.
• The risk of developing drug-resistant HBV mutants with lamivudine therapy requires careful consideration.

Conclusions:

• Lamivudine presents a viable treatment option for chronic hepatitis B in the elderly, balancing benefits against the risk of resistance.
• Continued research into new therapeutic strategies is essential for improving outcomes in this population.
• Vaccination remains critical for preventing HBV transmission, including household contacts of infected individuals.